RxDoctor Payments Data

Matthew Wilson, MD

Allergy · Huntington, WVNPI 1891726295

Payments from drug & device makers

$336,192in general payments, 2019–2025

Across 891 payments — averaging $377.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$230K
  • GSK$96K
  • CSL Behring$2K
  • Regeneron Healthcare Solutions, Inc.$2K
  • Optinose US, Inc.$1K
  • Pfizer$1K
  • plus $3K from 18 others

What the payments were for

  • Consulting fees$4,3454%
  • Speaking & faculty fees$90,52581%
  • Travel & lodging$9761%
  • Food & beverage$16,26014%
  • Education$2560%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few allergy providers in West Virginiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$1,295,566
Medicare patients
350
Services billed
47,804

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab79$345,038
NucalaMepolizumab72$287,886
Trelegy ElliptaFluticasone/Umeclidin/Vilanter252$217,019
Spiriva RespimatTiotropium Bromide176$150,278
HizentraImmun Glob G(Igg)/Pro/Iga 0-5014$137,703
XolairOmalizumab49$125,749
CuvitruImmun Glob G(Igg)/Gly/Iga Ov5014$122,970
Breo ElliptaFluticasone/Vilanterol164$97,204
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5012$85,179
TezspireTezepelumab-Ekko17$70,011
Dupixent SyringeDupilumab15$58,531
Fluticasone-SalmeterolFluticasone Propion/Salmeterol237$51,860
SymbicortBudesonide/Formoterol Fumarate135$43,229
Advair HfaFluticasone Propion/Salmeterol80$36,005
DuleraMometasone/Formoterol47$21,567

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKNucala, Trelegy Ellipta, Breo Ellipta, Incruse Ellipta$96,160$617,076521 claims
Takeda Pharmaceuticals U.S.A., Inc.Cuvitru, Gammagard Liquid$26$208,14926 claims
Boehringer IngelheimSpiriva Respimat, Combivent Respimat$348$155,975188 claims
CSL BehringHizentra$2,429$137,70314 claims
AstraZenecaTezspire, Symbicort$230,183$113,240152 claims
MerckDulera$15$21,56747 claims
Optinose US, Inc.Xhance$1,388$10,83314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy providers in West Virginiaon file to place this against a meaningful peer group, so we don't.

Other allergy in Huntington

Where these figures come from

Is this you, or does something look wrong? →